Oxcia is pleased to announce that three leading international experts in pulmonary fibrosis and clinical development have been recruited to its newly formed Strategic Advisory Board (SAB) in Idiopathic Pulmonary Fibrosis (IPF).
These distinguished advisors will provide strategic guidance and scientific expertise across key areas, including disease pathology and manifestations, clinical trial design, patient selection, data interpretation, and identification of unmet medical needs. Their insights will play a critical role in advancing Oxcia’s mission to develop innovative therapies for IPF and improve patient outcomes worldwide.
“We are very honored to welcome some of the most recognized experts and key opinion leaders in the field of lung fibrosis to our work,” says Ulrika Warpman Berglund, CEO at Oxcia. “Their outstanding translational and clinical expertise within IPF, combined with their strong commitment to improving patient outcomes and care, represents an invaluable asset to Oxcia. We look forward to working with them all to advance OXC-201 into clinical development.”
Briefly about the new Scientific Advisory Board members
Martin Kolb; Martin Kolb, M.D, PhD, is Professor in the Division of Respirology at McMaster University and Research Director at the Firestone Institute for Respiratory Health in Canada. He is an internationally recognised clinician-scientist specializing in interstitial lung disease (ILD), particularly idiopathic pulmonary fibrosis (IPF), with 350 peer-reviewed articles and has received prestigious awards. In 2024, Prof. Kolb was elected as a Fellow of the Canadian Academy of Health Sciences, one of the highest honours for Canadian healthcare researchers. He is the immediate past Chief Editor of the European Respiratory Journal and currently serves as Section Editor for ILD. He is a Principal Investigator and Steering Committee member in several national and international ILD clinical trials.
Elisabeth Bendstrup; Elisabeth Bendstrup MD, PhD, is professor at the Department of Respiratory Diseases and Allergy, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Denmark. Prof. Bendstrup is head of Center for Rare Lung Disease, the hospital unit for interstitial lung diseases and is clinical investigator and respiratory research lead. She combines her clinical work with research and is principal investigator in several national and international ILD clinical trials. Her research focuses mainly on pulmonary fibrosis and ultrarare lung diseases and she has published more than 250 peer-reviewed articles and has been a member of several international guideline task forces.
Jesper M. Magnusson; Jesper M Magnusson MD, PhD, is senior physician and associate professor at Sahlgrenska Department of Lung Medicine and Sahlgrenska Transplantation Centre at Sahlgrenska University Hospital in Gothenburg, Sweden. He combines clinical expertise with translational research. After his dissertation in 2018 he has since focused on advancing patient care through both academic medicine and clinical practice. His research interests bridge bench to bedside in Pulmonary fibrosis and Lung transplantation, with an emphasis on improving outcomes and integrating novel scientific findings into everyday healthcare. Dr Magnusson also has startup corporate experience as a board member of Mucolife Therapeutics.
Briefly about OXC-201
OXC-201 is a small molecule inhibitor of OGG1, and a potential breakthrough new approach for the treatment of IPF (idiopathic pulmonary fibrosis), other fibrotic conditions and inflammatory diseases. It has potential to halt disease progression, improve lung function, protect lung tissue and be well tolerated.
By targeting the DNA repair enzyme OGG, OXC-201 inhibits binding of OGG1 to DNA and thereby the modulation of gene transcription important for fibrosis and inflammation. OXC-201has been shown to protect against inflammation and fibrosis in several experimental disease models.
OXC-201 is patent protected and Oxcia AB has exclusive rights under the patent to develop and commercialize OXC-201.
The EIC (European Innovation Council) has awarded Oxcia AB a grant of 2.5 million euros for the project TOPFIBRO within the EIC-Transition program. This finances OXC-201 until the start of phase 1 in patients. More information is available at https://topfibro.oxcia.eu/
For more information, please contact:
Ulrika Warpman Berglund, ulrika.warpmanberglund@oxcia.com
Christina Kalderén, christina.kalderen@oxcia.com
Briefly about Oxcia AB
Oxcia’s aim is to improve and extend lives by developing new innovative treatments based on our unique technology platform, O2-DDR. Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe and effective treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two O2-DDR lead drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against idiopathic pulmonary fibrosis, and is in the preclinical phase. The portfolio also includes exploratory projects, e.g in psoriasis.
More information about Oxcia is available at www.oxcia.com